28,000 plummeted to 6,000!

28,000 dropped to 6,000 November 19, led by Jiangsu, covering 12 provinces including Jiangsu, Shanxi, Fujian, Hubei, Hunan, Hainan, Chongqing, Guizhou, Yunnan, Gansu, Xinjiang, and Corps to form an inter-provincial alliance to target drugs Coated balloons were purchased in a centralized manner, and the bid was opened in Nanjing
.
It is understood that the final price of coronary drug-coated balloons purchased by the alliance this time has dropped from RMB 20,000 to RMB 20,000 to RMB 6,300, with an average decrease of 70% and a maximum decrease of 77%
.
There are currently only 7 companies with drug-coated balloon approval documents, and a total of 8 products have all participated in this bidding
.
In the end, 6 companies and 7 products were selected, and 1 was eliminated, and the selection rate reached 88%
.
The selected companies include: Kaideno Medical Equipment (Wuhan) Co.
, Ltd.
, Shanghai Yingsheng Medical Technology Co.
, Ltd.
, Liaoning Yinyi Biotechnology Co.
, Ltd.
, Lepu (Beijing) Medical Equipment Co.
, Ltd.
, Braun Medical (Shanghai) International trading Co.
, Ltd.
, Shanghai medical Technology Co.
, Ltd.
Shen Qi, B.
Braun medical (Shanghai) international trading Co.
, Ltd
.
The selected products have complete specifications and models, both imported products and domestic products, especially all mainstream products currently in clinical use are selected, which can effectively meet the first-line clinical needs
.
According to the calculation of the annual demand of the 12 provincial alliance regions, it is estimated that more than 800 million yuan can be saved each year
.
The effect of the inter-provincial alliance's purchase price reduction will also radiate to the whole country, and the burden of related patients across the country is expected to be further reduced
.
Prices of high-value consumables for coronary interventional surgery have been reduced across the board.
With the announcement of the results of this round of centralized procurement, so far, all high-value consumables for coronary interventional surgery have been reduced in price
.
Coronary interventional surgery is a common method for clinical treatment of coronary heart disease.
The main high-value consumables required for surgery include coronary stents, balloons, catheters, guide wires, etc.
The prices of these high-value consumables have remained high for a long time.

.
In response to this, the National Medical Insurance Administration organized the nationwide centralized procurement of coronary stents in 2020, reducing the price of coronary stents from tens of thousands to less than 1,000 yuan.
Since then, it has instructed all provinces to purchase catheters and guide wires.
The price has dropped from several thousand yuan to several hundred yuan, and the cost of surgery for patients has dropped drastically
.
However, for the drug-coated balloons in high-value consumables for coronary intervention, large-scale procurement has not been carried out in the past due to insufficient market competition and other reasons.
The price is still relatively high, generally around 20,000 yuan, and one operation is possible.
After using a few, the burden on related patients is still heavy
.
Especially in June of this year, the well-known cardiovascular expert Hu Dayi revealed a truth in an interview with CCTV's "News Investigation" column: the stent is worthless, but the "drug balloon" is not in the scope of centralized procurement, then if you do a "drug balloon" "Sac", plus some of its supporting consumables, can also receive a fee of 20,000 to 30,000 yuan
.
Afterwards, the National Medical Insurance Administration instructed the Jiangsu Provincial Medical Insurance Administration to take the lead in forming an inter-provincial alliance, with the sword pointing to the drug-coated balloon
.
Moreover, it is not just the Jiangsu 12-province alliance.
In September this year, the Beijing-Tianjin-Hebei "3+N" alliance The centralized procurement of balloon medical consumables for coronary drugs was also launched
.
The two major procurement alliances in 12+13 provinces, such a wide range of bargaining, is enough to show the country's determination to continue to squeeze the moisture of high-value consumables, but from the magnitude of the price cut this time As well as the rules of centralized procurement, it seems that the situation of “low-price bidding” is slowing down
.
The decline in centralized procurement tends to be reasonable.
There are actually many points in the procurement rules for drug-coated balloons of the Jiangsu Interprovincial Alliance.
It is worthy for enterprises and other provinces to ponder and learn
.
First of all, in the bidding rules, the highest effective declaration price is set at 12,800 yuan (exceeding invalidity).
Limited by price correction and the number of candidates
.
In other words, companies can directly win the bid as long as they report 6,400 yuan, and they can complete 50% of their reported amount.
If they can be eliminated under this premise, there is only one answer.
.
.
And from this time Judging from the winning bid results, the winning prices are all around 6,300 yuan, with an average drop of 70%, which is not small, but the rules are more reasonable
.
Because under such rules, companies with high volume will not get out even if they quote a relatively large price
.
The same result is the second round of joint national procurement.
Although the decline is still 80%, judging from the number of companies that have won the bid and the feedback from the companies, it is basically still acceptable.
Many companies also said: Better than expected
.
The next stop for centralized procurement On August 23, at the national organization high-value medical consumables joint procurement office corporate training meeting, Gao Xue once pointed out: "It is not for everyone to fight for a bottomless low.
It must be relatively reasonable and profitable.
Our services can keep up
.
" Therefore, now everyone does not have to "listen to the collection and discoloration", and the core of the state-organized collection of consumables has always been the circulation cost that accounts for the main part of the price
.
The final price drop borne by the manufacturer lies in the profit margin of the channel.
If the profit margin of the channel is large, the impact on the manufacturer will be minimal
.
Several companies that have won the bid for the procurement of consumables can exclusively enjoy more than 80%-90% of the market share of public hospitals in the province (city), which is conducive to the increase of industry concentration and the expansion of the market share of leading companies
.
Therefore, under this game, the giants are riding the wind, and the only large-scale evacuations are small and medium-sized circulation companies.
How to “change their fate against the sky” has become a problem that most companies are facing, and this can only be left to Time
.
In short, no matter how the turbulent winds of the gathering, the trend of price-for-quantity will not change.

.
Recently, the National Medical Insurance Administration also issued the "Interim Measures for the Payment Management of Medical Consumables for Basic Medical Insurance (Draft for Comment)" and "Nambling Standards for the "Generic Names of Medical Insurance" Medical Consumables (Draft for Comments)", which indicates that medical consumables will be included Common name management and centralized medical insurance management for consumables are started
.
There is no doubt that under the unification of medical consumables and medical insurance, the high-value medical consumables industry will further promote the development of intensification, standardization and health
.